Understanding cancer lineage plasticity: reversing therapeutic resistance in metastatic prostate cancer

Leigh Ellis

doi:10.2217/pgs-2017-0039

Understanding cancer lineage plasticity: reversing therapeutic resistance in metastatic prostate cancer

Pharmacogenomics. 2017 May;18(7):597-600. doi: 10.2217/pgs-2017-0039. Epub 2017 May 4.

Author

Leigh Ellis^{1

2}

Affiliations

¹ Department of Oncologic Pathology, Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.
² Department of Pathology. Brigham & Woman's Hospital, Harvard Medical School, Boston, MA 02115, USA.

PMID: 28468521
DOI: 10.2217/pgs-2017-0039

No abstract available

Keywords: Androgen receptor; EZH2; castrate-resistant prostate cancer; epigenetic therapy; lethal prostate cancer; lineage plasticity; neuroendocrine; prostate cancer metastasis.

MeSH terms

Animals
Cell Lineage / physiology*
Cell Plasticity / physiology*
Drug Resistance, Neoplasm / physiology*
Humans
Male
Prostatic Neoplasms, Castration-Resistant / pathology*